12:00 AM
 | 
Apr 10, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Trocade: Phase III (discontinued)

Roche discontinued development of Trocade after interim Phase III data showed that the compound was unlikely to significantly prevent structural joint damage in RA...

Read the full 96 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >